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Norrisb, and Colin K. Combsa,*
aDepartment of Biomedical Sciences, University of North Dakota School of Medicine and Health 
Sciences, Grand Forks, ND, USA
bDepartment of Pharmacology and Nutritional Sciences and the Sanders Brown Center on Aging, 
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Abstract
Alzheimer’s disease (AD) brains are characterized by fibrillar amyloid-β (Aβ) peptide containing 
plaques and associated reactive microglia. The proinflammatory phenotype of the microglia 
suggests that they may negatively affect disease course and contribute to behavioral decline. This 
hypothesis predicts that attenuating microglial activation may provide benefit against disease. 
Prior work from our laboratory and others has characterized a role for the transcription factor, 
nuclear factor of activated T cells (NFAT), in regulating microglial phenotype in response to 
different stimuli, including Aβ peptide. We observed that the NFATc2 isoform was the most highly 
expressed in murine microglia cultures, and inhibition or deletion of NFATc2 was sufficient to 
attenuate the ability of the microglia to secrete cytokines. In order to determine whether the 
NFATc2 isoform, in particular, was a valid immunomodulatory target in vivo, we crossed an 
NFATc2−/− line to a well-known AD mouse model, an AβPP/PS1 mouse line. As expected, the 
AβPP/PS1 × NFATc2−/− mice had attenuated cytokine levels compared to AβPP/PS1 mice as well 
as reduced microgliosis and astrogliosis with no effect on plaque load. Although some species 
differences in relative isoform expression may exist between murine and human microglia, it 
appears that microglial NFAT activity is a viable target for modulating the proinflammatory 
changes that occur during AD.
Keywords
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INTRODUCTION
The transcription factor, nuclear factor of activated T cells (NFAT), has a classically 
described role in regulating immune cell phenotype [1–11]. Through calcineurin dependent 
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dephosphorylation, it is able to interact with additional transcription factors to regulate 
transcription of numerous genes in diverse immune cell types [2, 4, 5, 7, 8, 10, 12–19]. In 
addition, there are several isoforms of NFAT (NFATc1-c4 and NFAT5) that demonstrate both 
cooperative and separate effects on regulating cellular phenotype depending upon the 
context [20–26].
Significant work in the field has shown that NFAT proteins are not restricted to immune 
cells. In the brain, NFAT isoforms now have well described roles in regulating the 
phenotypes of neurons [27–32], astrocytes [33–42], and microglia [38, 43–47] during both 
normal physiology and disease. Although several extensive studies have characterized the 
ability of NFAT isoforms to regulate astrocyte phenotype during AD [33, 36, 39, 41, 48, 49], 
our prior work has focused on understanding the role of NFAT in regulating microglial 
phenotype during disease [46]. Comparing both in vitro and in vivo inhibitory strategies 
using pharmacologic and peptide-based inhibitors, we have observed a critical role of NFAT 
in regulating microglial activation state in response to amyloid-β (Aβ) stimulation [46].
Based upon importance of NFAT in regulating microglial proinflammatory activation and 
the fact that robust microgliosis is associated with Aβ plaque deposition during disease, we 
hypothesized that inhibition of microglial NFAT activity may be an attractive target for 
attenuating disease. We identified NFATc2 (NFAT1) as the most abundantly expressed 
isoform in primary murine microglia. Based upon this isoform predominance, we tested 
whether loss of NFATc2, in particular, was sufficient to attenuate the gliosis and 
proinflammatory changes associated with disease. Although NFAT isoforms may have 
redundant functions, it is feasible that NFATc2 may be more selectively targeted for future 
drug design compared to other isoforms [50]. To assess the relative importance of this 
isoform during disease, we examined the response of murine wild type and NFATc2 
knockout (NFATc2−/−) microglia and NFATc2 knockdown using siRNA to Aβ stimulation. 
We also crossed the NFATc2−/− mice to a well-known transgenic mouse model of AD, an 
AβPP/PS1 line. Although human NFAT isoform relative expression levels may differ from 
mice, our findings demonstrate that NFATc2 has a positive role in regulating microglial 
cytokine secretion in vitro and microglial activation phenotype in vivo and supports the idea 
that inhibiting NFAT activity is a valid approach for limiting microgliosis during AD.
MATERIALS AND METHODS
Animals
C57BL/6 and AβPP/PS1 (strain 005864 B6.Cg-Tg(APPswe,PSEN1dE9)85Dbo) transgenic 
mice were purchased from Jackson Laboratory (Bar Harbor, ME). The transgenic animals 
express the human AβPP, amyloid beta (A4) precursor protein and the human PSEN1, 
presenilin 1. NFATc2−/− (strain 000197-UNC B6; 129-Nfatc2tm1Rao/Mmnc) mice were 
purchased from Mutant Mice Regional Resource Center (MMRRC). These mice have a 
complete loss of NFATc2 (NFAT1) protein due to disrupted gene. NFATc2−/− mice were 
bred with AβPP/PS1 mice to produce F1 offspring. The heterozygous F1 generation of 
AβPP/PS1xNFATc2+/− and NFAT+/− mice were then bred to each other to produce F2 
offspring consisting of AβPP/PS1, wild type (WT), NFATc2−/−, NFATc2+/−, AβPP/
PS1xNFATc2−/−, and AβPP/PS1xNFATc2+/−. AβPP/PS1, wild type (WT), NFATc2−/−, and 
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AβPP/PS1xNFATc2−/− mice with the same genetic background were then maintained at the 
University of North Dakota’s Center for Biomedical Research. This breeding strategy also 
insured that littermates were used for comparison. The AβPP/PS1xNFATc2−/− mice are now 
available from MMRRC (B6.Cg-Nfatc2tm1Rao Tg(APPswe,PSEN1dE9)85Dbo/Mmmh). 
Only male mice were used at 8 months of age with an n = 8–10 per genotype. All animals 
were maintained with standard housing conditions in a 12-h light/dark cycle with ad libitum 
food and water until use. All animal experiments were approved by the UND Institutional 
Animal Care and Use Committee (IACUC). The investigation conforms to the National 
Research Council of the National Academics Guide for the Care and Use of Laboratory 
Animals (8th edition).
Primary cultures
Microglia were grown from the brains of C57BL/6 and NFATc2−/− mice at postnatal day 1–
3 according to our prior protocols [51]. Microglia were isolated from mixed glial cultures at 
14 days in vitro for use. The remaining astrocytes were passaged and plated for use 
according to our prior work [52]. Microglia and astrocyte cultures were maintained in 
DMEM/F12 (Life Technologies, Carlsbad, CA) media supplemented with 10% heat 
inactivated fetal bovine serum, 5% heat inactivated horse serum and antibiotics (penicillin, 
streptomycin, neomycin) at 37°C and 5% CO2. Primary cortical neurons were grown from 
E16 mouse brains in Neurobasal media with B27supplements (Life Technologies, Carlsbad, 
CA) according to our prior protocol [53].
Microglial cell lines, BV2 and HMC3
Immortalized murine microglial BV2 cells were obtained from Dr. Gary E. Landreth, 
Cleveland, Ohio. Human microglial cell line, HMC3, obtained from the ATCC (Manassas, 
VA), were maintained in DMEM/F12 (Gibco RBL, Rockville, MD) supplemented with 10% 
heat-inactivated fetal bovine serum (FBS), 5% horse serum, and 1% antibiotics (penicillin, 
streptomycin, neomycin).
NFAT knockdown using siRNA
Murine microglial cells, BV2, were transfected with an eGFP expression plasmid, control 
siRNA, or mouse siGENOME SMARTpool siRNA for NFATc1, NFATc2, and NFATc4 (GE 
Dharmacon, Lafayette, CO) using the appropriate Nucleofector program as described by the 
manufacturer (Amaxa Inc., Gaithersburg, MD). Human microglial cells, HMC3, were 
transfected with an eGFP plasmid or human siGENOME SMARTpool NFATc4 siRNA 
using Lipofectamine 3000 according to the manufacturer’s protocol. pCMV-eGFP plasmid 
was a gift from Dr. Saobo Lei and Nicholas Cilz and was used as transfection control in all 
knockdown experiments. Cells were lysed using RIPA buffer (20mM Tris, pH 7.4, 150mM 
NaCl, 1mM Na3VO4 10mM NaF, 1mM EDTA, 1mM EGTA, 0.2mM phenylmethylsulfonyl 
fluoride, 1% Triton X-100, 0.1% SDS, and 0.5% deoxycholate) 48-h post-transfection and 
lysates used for western blot analyses.
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Cell stimulation
Primary murine microglia were stimulated with or without lipopolysaccharide (LPS, Sigma-
Aldrich, St. Louis, MO) or human Aβ1–42 (rPeptide, Bogart, GA) prepared in distilled water 
and used immediately as a mixture of conformations. Cells were preincubated 30 min with 
or without 1 μM FK506 (Alexis Biochemicals, Enzo Life Sciences, Farmingdale, NY) or 
vehicle control (DMSO) prior to Aβ or LPS stimulations. BV2 cells were transfected with 
control, NFATc1, or NFATc2 siRNA using nucleofection. Cells were stimulated with either 
10 μM scrambled Aβ1–42 or different concentrations of monomeric Aβ1–42 or fibrillar 
Aβ1–42 at 48-h post transfection. Media from stimulated cells was collected 24-h post-
treatment and TNF-α levels quantified using commercial ELISA (R&D Systems, 
Minneapolis, MN).
Western blotting
Hippocampi of male 8-month-old WT, NFATc2−/−, AβPP/PS1, and AβPP/PS1xNFATc2−/− 
mice (n = 8) were collected from the left hemispheres, flash frozen, lysed in RIPA buffer, 
and resolved using 10% SDS-PAGE. Western blot analyses were performed with antibodies 
specific for different NFAT isoforms (NFAT c1, c3, c4, Santa Cruz Biotechnology, Dallas, 
TX; NFATc2, Cell Signaling Technology, Danvers, MA), AβPP (Y188, Abcam, Cambridge, 
MA), PSD95 (Cell Signaling Technologies), synaptophysin (EMD Millipore, Billerica, 
MA), and TNFα (Abcam, Cambridge, MA). Western blots were also performed from 
culture lysates of primary mouse microglia, neuron, and astrocytes using the same anti-
NFAT antibodies. In all cases, loading control antibodies recognizing either α-tubulin or 
actin were used for densitometric quantitation using Adobe Photoshop software (Adobe 
Systems, San Jose, CA).
NFAT c1 and c2 transcription factor activation assay
NFATc1 and c2 transcription factor activity assays were performed using nuclear lysates 
prepared from primary mouse microglia cultures. Cells were plated in serum free 
DMEM/F12 media overnight before stimulation with 10 μMAβ1–42 for 1 h at 37°C. After 
the stimulation was over, the plates were washed with PBS and nuclear lysates were 
prepared following the manufacturer protocol (Active Motif, Carlsbad, CA). The amount of 
protein in the nuclear lysates was determined by the Bradford assay [54] then used to 
perform activity assessments using the TransAm NFATc1 kit (Active Motif, Carlsbad, CA) 
with slight modification of the manufacturer protocol to substitute with an anti-NFATc2 
detection antibody for quantifying NFATc2 activity as well. Activities of both NFATc1 and 
c2 were measured with a plate reader (Biotek, Winooski, VT) at 450 nm with a reference 
filter at 630 nm.
Enzyme-linked immunosorbent assay (ELISA)
Commercial cytokine ELISAs were performed using media collected from murine microglia 
or BV2 cells stimulated with or without LPS, Aβ1–42, or FK506 for 24 h according to the 
manufacturer’s protocols (R&D Biosystems, Minneapolis, MN).
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Tissue cytokine mRNA Real-time PCR
Flash frozen spleens from 8-month-old WT, NFATc2−/−, AβPP/PS1, and AβPP/
PS1xNFATc2−/− mice were lysed using Qiazol RNA lysis buffer and RNA was isolated 
using Qiagen RNeasy Lipid Tissue Kit (Qiagen, Germantown, MD) according to the 
manufacturer’s protocol. For amplification of mRNA for TNF-α expression, 150 ng of RNA 
was used as a template for performing real-time PCR using the iTaq Universal SYBR Green 
One-Step kit (Bio-Rad, Hercules, CA). Fold change in the level of mRNA expression for 
each group was calculated as 2∧-ΔΔCt with respect to average mRNA expression of the WT 
group. The values obtained for 5 animals per group were averaged and plotted (±SD; *p < 
0.05).
Immunohistochemistry
For mouse brain histology, right hemispheres from brains of 8-month-old WT, NFATc2−/−, 
AβPP/PS1, and AβPP/PS1xNFATc2−/− mice (n = 8) were collected, fixed in 4% 
paraformaldehyde for 48 h, then changed to 30% sucrose in PBS for 14 days changing the 
sucrose every 4 days. The fixed tissue was then embedded in a matrix for 40 μM serial 
sectioning (Neuroscience Associates, Knoxville, TN). Serial sections per well were 
immunostained using anti-Iba-1, CD68, GFAP (Cell Signaling technology, Danvers, MA), 
and Aβ (4G8, Biolegend, San Diego, CA) antibodies. NFATc2 immunostaining was 
performed with anti-NFATc2 (Cell Signaling Technology, Danvers, MA) on brain sections 
from AβPP/PS1 mice. Antibody binding was visualized using Vector VIP as the chromogen. 
A set of serial sections were also stained using the Campbell-Switzer stain (Neuroscience 
Associates, Knoxville, TN). In order to quantitate immunostaining, 1.25X pictures of 3 
consecutive sections (960 μm apart) throughout the temporal cortex region were obtained. 
Images were taken using an upright Leica DM1000 microscope and Leica DF320 digital 
camera system. Optical densities from similar temporal cortex regions for each brain section 
were measured using Adobe Photoshop software. The optical density values per condition (4 
conditions), per brain (10 brains per condition) and per section (3 sections per brain) were 
obtained, averaged and plotted. Representative images using 20X magnification are shown.
Statistical analysis
Data are shown as mean ± standard deviation (SD) and representative of three independent 
experiments unless noted otherwise. Values statistically different from controls were 
determined using Student’s t test, one-way ANOVA, or two-way ANOVA where 
appropriate. The Tukey-Kramer post hoc test or Holm-Sidak multiple pair-wise comparisons 
were used to determine p-values where applicable.
RESULTS
NFATc2 was activated by Aβ stimulation in murine microglia cultures
In order to assess the relative abundance of NFAT isoform expression across cell types in the 
brain, we compared protein levels of NFAT isoforms in cultured murine microglia, 
astrocytes, and neurons by western blot analysis. As expected, multiple molecular weight 
bands were detected for each isoform across cell types consistent with the many splice 
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variants that exist for the proteins [55]. Although detectable levels of NFATc1, c2, and c4 
were observed in microglia, NFATc2 appeared the most abundant isoform (Fig. 1A). To 
validate that the isoforms were behaving as expected, microglia were stimulated with Aβ 
and activity of NFATc1 and c2 were quantified. Surprisingly, Aβ stimulated increased 
activity of only NFATc2 and not NFATc1 perhaps reflecting some specificity of response 
(Fig. 1B). Although the banding pattern of anti-NFAT antibodies on a western blot varied 
depending upon their isoforms, the antibodies used for this study were validated using 
siRNA against their respective NFAT proteins. The murine microglial cell line, BV2, was 
transfected with siRNA for NFATc1, NFATc2, NFATc3, and NFATc4. Western blot analysis 
demonstrated decreased protein in the NFATc1 and NFATc2 knock down samples with no 
difference in NFATc3 blots since they were negative regardless (Fig. 1C). NFATc4 
knockdown did not attenuate band detection of the NFATc4 western blots suggesting that 
this antibody was not specific for murine NFATc4 (Fig. 1C). However, NFATc4 siRNA 
knockdown using the human microglial cell line, HMC3, demonstrated a clear attenuation of 
western blot detection demonstrating the specificity of the NFATc4 antibody for human 
protein and validating expression of NFATc4 in human microglia (Fig. 1D). This data 
suggests a possible difference in abundance of particular NFAT isoform(s) across species.
NFATc2 knockdown had an attenuated proinflammatory phenotype following Aβ or LPS 
stimulation
Based upon the observed increase in NFATc2 activity, we hypothesized that it would be 
required for the subsequent proinflammatory phenotype changes that occurred in microglia 
upon Aβ stimulation. To test this idea, cultures of NFATc2−/− and C57BL/6 microglia were 
compared following Aβ and bacterial endotoxin LPS stimulation. Morphologically, 
NFATc2−/− microglia appeared similar to C57BL/6 cells with robust immunoreactivity for 
the microglial marker, CD68 (Fig. 2A). Moreover, the absence of NFATc2 expression did 
not appear to reflect in any development compensatory increase in relative levels of other 
isoforms in these cells (Fig. 2B). However, stimulation of either cell type with Aβ or LPS 
demonstrated significantly attenuated secretion of both IL-6 and TNFα in the NFATc2−/− 
cells compared to C57BL/6 (Fig. 2C-F). More importantly, although pretreatment of 
C57BL/6 microglia with the calcineurin/NFAT inhibitor, FK506 [56, 57], was sufficient to 
attenuate cytokine secretion, it had no inhibitory ability on the NFATc2−/− cells (Fig. 2E,F). 
This demonstrated that the drug inhibitory effect in microglia required NFATc2 activity. This 
was further validated using siRNA knockdown of NFATc2 in the BV2 cells. Cells 
transfected with NFATc2 siRNA were treated with either scrambled Aβ or varying 
concentrations of monomeric or fibrillar Aβ. Monomeric and fibrillar Aβ dose-dependently 
stimulated TNFα secretion from the BV2 cells (Fig. 2G). As expected, siRNA knockdown 
of NFATc2 attenuated cytokine secretion (Fig. 2G). However, siRNA knock down of 
NFATc1 also attenuated Aβ-stimulated TNFα secretion although less effectively than 
NFATc2 knockdown (Fig. 2G). Nevertheless, this data suggested that NFATc1 may also 
have some role in regulating the Aβ-stimulated phenotype in microglia.
AβPP/PS1xNFATc2−/− mice had attenuated brain cytokine levels
Based upon the relative importance of NFATc2 in regulating microglial activation observed 
in vitro, we hypothesized that it would have a similar importance in vivo. In order to test this 
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idea, we crossed the NFATc2−/− mice to a common AD mouse model of disease, AβPP/PS1 
mice. Consistent with the in vitro observation, plaque associated microglia in 8-month-old 
mice demonstrated robust NFATc2 immunoreactivity in the AβPP/PS1 mice brains (Fig. 
3A). More importantly, hippocampi from the AβPP/PS1xNFATc2−/− mice had attenuated 
membrane-associated TNFα levels compared to the AβPP/PS1 brains demonstrating the 
relative importance of NFATc2 in regulating microglial phenotype in vivo (Fig. 3B,F). To 
assess how significant the effect of NFATc2 deletion was on peripheral immune phenotype, 
TNFα mRNA levels were quantified from spleens. Surprisingly, TNFα mRNA levels were 
elevated in the AβPP/PS1 mice compared to WT mice demonstrating an overall systemic 
immune activation in these transgenic mice (Fig. 3G). However, TNFα mRNA was also 
significantly elevated in AβPP/PS1xNFATc2−/− spleens compared to WT mice (Fig. 3G). 
This is consistent with broader isoform expression in peripheral immune cells and likely 
redundancy of function. Additionally, an increase in protein levels of PSD95 but not 
synaptophysin that was observed in the AβPP/PS1 mouse hippocampi was attenuated in the 
AβPP/PS1xNFATc2−/− brains (Fig. 3D,E). AβPP/PS1xNFATc2−/− mice also had a slightly 
attenuated overexpression of AβPP compared to AβPP/PS1 mice bringing protein levels 
down to no significance from WT mice (Fig. 3C). These data demonstrated the importance 
of NFATc2 in regulating several changes in the AβPP/PS1 brains including proinflammatory 
state.
Aβ plaque load was not significantly different between AβPP/PS1 and AβPP/
PS1xNFATc2−/− brains
In order to test whether the potential reduction in AβPP overexpression or an attenuated 
microglial activation phenotype, we observed in the AβPP/PS1xNFATc2−/− mice resulted in 
altered levels of Aβ accumulation in the brain, we next quantified plaque load in the 8-
month-old mice. However, plaque load assessed by both anti-Aβ immunoreactivity and the 
Campbell-Switzer stain revealed no differences between the AβPP/PS1 and AβPP/
PS1xNFATc2−/− mice (Fig. 4). This demonstrated that attenuated NFATc2 expression had no 
adverse effects on plaque accumulation.
Microgliosis and astrogliosis were attenuated in the AβPP/PS1xNFATc2−/− versus 
AβPP/PS1 mouse brains
Based upon the attenuated TNFα levels we observed in the AβPP/PS1xNFATc2−/− mice, we 
predicted attenuated activation of microglia, in particular. Quantitation of microgliosis via 
both CD68 and Iba-1 immunoreactivity demonstrated a significant reduction in AβPP/
PS1xNFATc2−/− brains compared to AβPP/PS1 (Fig. 5). Interestingly, the AβPP/
PS1xNFATc2−/− mouse brains also demonstrated a significantly lower level of astrogliosis, 
assessed by GFAP immunoreactivity, when compared to the AβPP/PS1 mouse brains (Fig. 
5). These findings supported a role for NFATc2 in regulating proinflammatory changes in 
the brain particularly with respect to AD.
DISCUSSION
From our work as well as others it is clear that microglia express NFAT isoforms and these 
have a role in regulating cellular phenotype [38, 43–47]. In this study, we found that 
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NFATc2 is the most abundantly expressed isoform in murine microglia and its activity was 
selectively increased by Aβ stimulation. Moreover, NFATc2−/− microglia had significantly 
decreased TNFα and IL-6 secretion following Aβ and LPS activation. Consistent with the 
high level of NFATc2 expression, we observed in microglia in vitro, deletion of NFATc2 
resulted in significant attenuation of proinflammatory TNFα levels and microgliosis in the 
AβPP/PS1xNFATc2−/− mice. Although NFATc2 was critical in regulating Aβ-stimulated 
cytokine secretion in murine cells, relative NFAT isoform expression level murine compared 
to human microglia is still needed. Nevertheless, the collective data support the idea that 
NFAT is an attractive target for attenuating gliosis in AD.
The possibility of selectively targeting NFATc2 compared to other isoforms remains 
appealing given the fact that it has a c-Jun N-terminal kinase (JNK) phosphorylation 
activation epitope unique from other NFAT isoforms [50]. This suggests it may be feasible to 
design small molecules for isoform selective inhibition. However, NFATc2−/− mice have 
been reported to have an enhanced TH2 immune response [58], reduced muscle growth [59], 
dysfunctional chondrogenesis [60], and osteoarthritis [61]. In addition, it appears that aged 
NFATc2−/− mice can develop anemia and lymphocytosis as well [62]. Therefore, it is 
possible that long term complete inhibition of this NFAT isoform may have unwanted 
adverse effects. Nevertheless, the clinical utility of the widely used indirect NFAT inhibitors 
cyclosporine A (CsA) and FK506 [56, 57, 63] validate that NFAT inhibition, in principle, is 
a valid approach for long-term immunomodulation. Nevertheless, selective NFAT inhibition 
strategies are still required since adverse side effects of both CsA and FK-506 exist due to 
their indirect inhibitory mechanism that relies on inhibition of the phosphatase, calcineurin 
[63]. For example, small molecule [64, 65] as well as peptide based inhibitors [33, 36, 39, 
41, 45, 66–70] of NFAT but not calcineurin have been described. It is likely that continued 
preclinical development in this area will produce agents with the immunomodulatory action 
of NFAT inhibition without the adverse consequences of nephrotoxicity associated with 
FK-506 and CsA [71, 72].
We have focused our study on primarily NFATc2 in microglia but appreciate that other 
isoforms are expressed as well. Indeed, our data showed potential differences in NFATc4 
expression between human and mouse microglia. Although our Aβ stimulation showed no 
increase in NFATc1 activity, it is likely that these other isoforms may also be involved in 
regulating microglial activation particularly in vivo and future work with isoform selective 
inhibition or knockdown may better elucidate this. Defining the relative contribution of 
isoforms in regulating microglial phenotype is particularly important. Future work assessing 
particularly the role of individual isoforms in regulating human and murine microglial 
phenotype will be of interest.
Although we remain interested in microglial NFAT, it is clear that this transcription factor 
has an important role in regulating astrocyte activation as well. Indeed, since our animals 
have NFATc2 deleted from all cells we cannot exclude the possibility that the decrease in 
gliosis and cytokine levels observed in the AβPP/PS1xNFATc2−/− was not also due to loss of 
astrocyte activation. In fact, we did observe a significant decrease in GFAP positive 
astrocytic staining in these mice. This is entirely consistent with prior work demonstrating 
that astrocytic NFAT is important in regulating cellular phenotype during AD [33, 36, 39, 
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41]. Consistent with this pleiotropic role of the transcription factor, our data showed 
decreased gliosis, both microgliosis and astrogliosis, in the brains of AβPP/PS1xNFATc2−/− 
mice supporting the idea that NFATc2 is a relevant immunomodulatory transcription factor 
in the brain. However, based upon the heterogeneity of isoform expression, it is clear that 
dissection of isoform and cell selective function is needed to better determine the utility of 
targeting these transcription factors for therapeutic discovery.
It was somewhat surprising to find that protein levels of the post-synaptic marker, PSD95, 
were increased in the AβPP/PS1 brains and this was attenuated by NFATc2 deletion. 
However, in the same lysates we did not observe any difference in the pre-synaptic marker 
protein, synaptophysin. It is interesting to speculate that expression of the human mutant 
AβPP or PS1 was sufficient to produce a dysregulation of the post-synaptic compartment 
that was NFATc2 dependent. It is clear that neurons also express the NFATc2 isoform and it 
has a critical role in regulating trophic factor stimulated axon growth [29]. More importantly, 
prior work has shown that oligomeric Aβ stimulates increased neuronal calcineurin activity 
and spine loss that is NFAT dependent supporting the notion that NFAT has some role in 
regulating the post-synaptic compartment and Aβ toxicity [30, 32, 73].
Another interesting consideration is the role of Aβ as a putative transcription factor 
regarding its ability to regulate both AβPP and BACE expression via binding to an AβID in 
their promoters [74, 75]. Moreover, NFAT has a reported role in regulating BACE1 
expression as well. NFATc4 has been demonstrated to regulate BACE1 expression and bind 
to a region in the BACE1 promoter [76]. Similarly, NFATc2 has a reported binding site in 
the BACE1 promoter [77]. This suggests that Aβ might stimulate increased NFAT activity to 
drive acquisition of a proinflammatory phenotype in the microglia but also increased Aβ 
production which might feed-forward to stimulate additional NFAT activity and Aβ 
production.
Based upon our observations that the decreased microgliosis and astrogliosis did not 
correlate with altered plaque load in the AβPP/PS1xNFATc2−/− mice, these mice may not 
only provide a model of assessing whether or not NFATc2 is involved in the 
proinflammatory changes of disease but also whether reducing inflammatory changes 
independent of Aβ plaque load is sufficient to offer protection against memory decline. Prior 
work, although directed at astrocytic NFAT, has shown that attenuating NFAT activity is 
sufficient to improve memory performance in an AD mouse model suggesting that similar 
findings would occur in these mice [36]. Future work with behavioral outcomes and 
microglial selective NFATc2 inhibition will better resolve the question of which cell type, 
neurons, astrocytes, or microglia, is the most reasonable target for AD. Collectively, our 
findings support the ongoing interest in shifting study of NFAT biology from the peripheral 
immune system to brain for the purpose of understanding its ability, perhaps in an isoform 
selective fashion, to regulate the proinflammatory changes that occur during injury and 
disease.
In conclusion, these data demonstrate both in vitro and in vivo in a mouse model of AD that 
the transcription factor NFATc2 has a role in regulating microglial activation. This suggests 
the possibility of isoform selective inhibitor design to limit inflammation in AD.
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Fig. 1. 
Aβ1–42 stimulation increased NFATc2 activity in mouse microglia. Primary microglia, 
astrocyte, and cortical neuron cultures were grown from embryonic day 16 (neurons) or 
postnatal day 1–3 (astrocytes/microglia) C57BL/6 mouse brains. A) Cultures were lysed in 
RIPA buffer, quantified, separated by 10% SDS-PAGE, and western blotted using antibodies 
that recognized NFATc1, c2, c3, and c4 with an anti-α-tubulin antibody as a loading control. 
B) Microglia cultures were stimulated with 10 μM Aβ1–42 for 1 h followed by nuclear 
isolation and a colorimetric transactivation quantitation assay for both NFATc1 and NFATc2 
using a commercial plate-based assay. The graph shown is the average ± SD optical density 
normalized by nuclear protein content (Normalized O.D.) of 3 independent experiments, *p 
< 0.05. C) BV2 cells transfected with transfection control (eGFP expressing plasmid), 
control siRNA, siRNA for NFATc1, NFATc2, NFATc3, or NFATc4 were lysed in RIPA 
buffer and lysates western blotted using anti-NFATc1, anti-NFATc2, anti-NFATc3, and anti-
NFATc4 antibodies. D) Human microglia cell line, HMC3, was transfected with an eGFP 
expressing plasmid or siRNA for NFATc4 and lysates western blotted using an anti-NFATc4 
antibody.
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Fig. 2. 
NFATc2 knock out microglia had attenuated cytokine secretion following both Aβ1–42 and 
LPS stimulation. Microglia cultures were grown from NFATc2−/− and C57BL/6 postnatal 
day 1–3 mouse brains. A) Microglia were plated overnight in serum free media then fixed in 
4% paraformaldehyde for immunostaining using anti-CD68 antibodies and Vector VIP as 
the chromogen. Immunostains are representative of 3-4 independent cultures. B) 
Alternatively, microglia were lysed in RIPA buffer, quantified, separated by 10% SDS-PAGE 
and western blotted using anti-NFATcl, NFATc2, NFATc3, and NFATc4 antibodies with 
anti-actin antibodies used as the loading control. Blots are from 3-4 independent cultures. 
Microglia cultures were also stimulated overnight in serum free media in the absence or 
presence of 10 μM Aβ1–42 or 2.5 ng/mL LPS. Media was collected to quantify secretion of 
IL-6 (C) and TNFα (D) by commercial ELISA. Graphs are the average ± SD of 3 
independent experiments, *p < 0.05. Microglia cultures were stimulated overnight with or 
without 10 μM Aβ1–42 or 1 μM FK506 and the media was collected to quantify IL-6 (E) and 
TNFα (F) levels by commercial ELISA. Graphs are the average ± SD of 3 independent 
experiments, *p < 0.05, #p < 0.05 from respective control. (G) Murine microglia cells, BV2, 
were either non-transfected or transfected with siRNA for NFATc1 and NFATc2. Cells were 
stimulated with either scrambled Aβ, monomeric Aβ, or fibrillar Aβ 48-h post-transfection 
and the media used for quantifying TNFα levels using ELISA. TNFα concentrations were 
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averaged and graphed ± SD from 3 independent experiments, *p < 0.05 and #p < 0.05 from 
their respective non-transfected controls, $p < 0.05 from respective Aβ treatment.
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Fig. 3. 
Brains of AβPP/PS1xNFATc2−/− mice had attenuated TNFα levels compared to AβPP/PS1 
mice correlating with loss of plaque-associated NFATc2 immunoreactivity. A) Right brain 
hemispheres from male AβPP/PS1 mice were fixed, sectioned and immunostained using 
anti-NFATc2 antibody. Images shown are representative from temporal cortex at 20X and 
63X magnification. B) Male WT, NFATc2−/−, AβPP/PS1, and AβPP/PS1xNFATc2−/− mice 
at 8 months of age (n = 8–10) were collected for western blot analysis. Hippocampi were 
collected from left hemispheres and lysed, quantitated, and separated by 10% SDS-PAGE 
along with positive control mouse recombinant TNFα (rmTNFα) for western blot analysis 
using anti-NFATc2, AβPP (C), PSD95 (D), Synaptophysin (E), and TNFα antibodies (F). 
Antibodies recognizing α-tubulin were used as loading controls. Blots shown are 
representative of 8 animals per genotype. Graphs are the average ± SD of optical densities of 
individual antibodies normalized to their respective loading control (Normalized O.D.) from 
8 animals per condition (genotype), *p < 0.05. G) Levels of TNF-α mRNA from spleens 
were determined using real time PCR. Fold change in the level of mRNA expression for 
each group was calculated as 2∧-ΔΔCt with respect to average mRNA expression of the WT 
group. The values obtained for 5 animals per group were averaged and plotted ± SD, *p < 
0.05.
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Fig. 4. 
Brains of AβPP/PS1xNFATc2−/− mice had no differences in plaque load compared to 
AβPP/PS1 mice. Male WT, NFATc2−/−, AβPP/PS1, and AβPP/PS1xNFATc2−/− mice at 8 
months of age (n = 10) were collected for immunohistochemical analysis. Right hemispheres 
were fixed, serially sectioned and (A) plaques visualized using either the Campbell-Switzer 
histologic stain or anti-Aβ (4G8) immunostaining. Images shown are representative from 
the temporal cortex of 10 animals per genotype. B) Immunostaining intensity was quantified 
as described in the Materials and Methods. Graphs are the average ± SD of normalized 
optical densities (Normalized O.D.) of immunostaining from the temporal cortex of 10 
animals per condition (genotype), *p < 0.05.
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Fig. 5. 
Brains of AβPP/PS1xNFATc2−/− mice had attenuated gliosis compared to AβPP/PS1 mice. 
Male WT, NFATc2−/−, AβPP/PS1, and AβPP/PS1xNFATc2−/− mice at 8 months of age (n 
=10) were collected for immunohistochemical analysis. Right hemispheres were fixed, 
serially sectioned and gliosis was visualized using (A) anti-CD68, Iba-1, or anti-GFAP 
immunostaining to visualize microglia and astrocytes, respectively. Images shown are 
representative from the temporal cortex of 10 animals per genotype. B) Immunostaining 
intensity was quantified as described in the Materials and Methods. Graphs are the average ± 
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SD of normalized optical densities (Normalized O.D.) of immunostaining from the temporal 
cortex of 10 animals per condition (genotype), *p < 0.05.
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